Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives patent confirmation for Nexium

AstraZeneca receives patent confirmation for Nexium

10th October 2007

AstraZeneca has received confirmation from the European Patent Office (EPO) that its European process patent for Nexium is valid in its amended form.

The patent EP 0773940 was opposed by the German manufacturer Ratiopharm but the EPO ruling has upheld claims one and two for Nexium while claims three and four have seen only minor amendments made.

Nexium’s patent covers a process for manufacturing esomeprazole and its salts in many of the EU member states as well as in Switzerland, Monaco and Liechtenstein.

Even in its amended form the patent still covers the manufacturing process for Nexium and the company has pledged its confidence in the intellectual property portfolio protecting Nexium.

The portfolio includes additional patents with expiration dates ranging from 2009 to 2018 in addition to the EP 0773940 patent which expires in 2015.

Nexium also has data exclusivity valid until March 2010 in most major European markets.

Last month, AstraZeneca announced the appointment of Simon Lowth as chief financial officer and an executive officer of the company, with the move to be effective from November 5th 2007.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.